Provention Bio Inc (NQ: PRVB )
24.98 UNCHANGED Last Price Updated: 4:00 PM EDT, Apr 26, 2023 Add to My Watchlist
All News about Provention Bio Inc
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
April 12, 2023
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies...
Provention Bio's Earnings Outlook
March 15, 2023
4 Analysts Have This to Say About Provention Bio
March 14, 2023
12 Health Care Stocks Moving In Monday's Intraday Session
March 13, 2023
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following